A 34-year-old male is experiencing hair loss on the sides of his head, with inflammation and itchiness, while the top remains thick. He is using topical dutasteride and keto shampoo to address the issue.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
A user reported losing 150-250 hairs daily after 9 months on dutasteride, despite previously stabilizing hair loss with finasteride and minoxidil. Blood tests showed high DHT levels, and the user is unsure if they should continue the current treatment.
The user is considering adding Stemoxydine to their hair loss regimen, as they already use topical finasteride with rosemary and cannot use Minoxidil. They are seeking feedback on Stemoxydine and Alphatradiol, and another user mentions 2-deoxy-d-ribose as a potential option.
A 40-year-old shared progress pictures showing results after 3.5 months of using dutasteride for hair loss. The conversation likely discusses this specific treatment and its effects on hair regrowth.
Alfatradiol helps reduce hair shedding and itching, and is effective for mild hair loss. Users combine it with treatments like fluridil, minoxidil, and sometimes consider finasteride.
The conversation discusses using shou wu chih or fo-ti/he shou wu for hair loss, with OP noticing stiffer beard and body hair. A user warns about potential liver damage from fo-ti and questions the effectiveness of alternative medicine.
ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
The user is using Minoxidil, RU58841, CB-03-01, WAY-316606, Ketoconazole, MK-677, and derma stamping to treat hair loss and has noticed new hair growth, especially around the temples and hairline. They apply different treatments at various times of the day and have seen improvements in skin condition and body hair texture.
A 24-year-old male shares his two-month progress on hair regrowth using 0.5mg Dutasteride, 2.5mg Minoxidil, 10mg Biotin, and Ketoconazole shampoo, noting significant crown improvement. Users discuss the effectiveness of oral Minoxidil, with some expressing skepticism about photo angles and the necessity of Biotin unless deficient.
After 11 years on Finasteride, a user's hair is thinning again, suggesting hair may become more sensitive to DHT with age. They plan to introduce Dutasteride once a week, as they cannot tolerate Minoxidil.
A user shared their positive experience with hair regrowth using minoxidil, hormone replacement therapy, and cyproterone acetate during their male-to-female transition. Another user discussed their successful hair transplant after transitioning and using finasteride, highlighting the challenges of hair loss and regrowth during transition.
OP experienced diffuse thinning for 11 years and used Minoxidil and Finasteride previously. They now use Pyrilutamide 0.5% and Alfatradiol 0.1%, resulting in significantly reduced hair loss.
The conversation is about hair loss treatments, specifically a stack including topical Ashwagandha, Copper Peptide, Gotu Kola, Ketoconazole, and PDA. One user found Topical and Sub-Q GHK-CU effective.
A user shared their 4-month progress using 2.5mg minoxidil, 1mg finasteride, and 10mg biotin, noting slight testicular discomfort initially but no significant hairline changes yet. Another user reported similar treatment results, with hair darkening at the scalp center and small temple hairs.
The user has androgenetic alopecia (AGA) and low Vitamin D levels, and they started using topical minoxidil (5%). They are considering finasteride but are concerned about side effects and are advised to seek mental health support.
The conversation is about someone experiencing hair regrowth using Minoxidil and Dutasteride, along with other treatments. They report their hairline is improving and their forehead appears smaller.
User noticed beard and sideburn hair loss, and thinning eyebrows, diagnosed with alopecia barbae and male pattern baldness, and prescribed Desonide cream. User seeks feedback on Desonide cream.
A user has been taking finasteride for 5 months with no improvement in diffuse hair loss and suspects high levels of prolactin, cortisol, progesterone, and DHEAS, as well as iron, might be contributing to the issue. They are also taking vitamin D to address a deficiency.
A 39-year-old shared a 17-month hair loss treatment update using Dutasteride, Minoxidil, Nizoral shampoo, and a 1.5mm derma roller, noticing significant results after 9-12 months. They also maintain a healthy lifestyle and manage side effects like dry skin with moisturizer.
User redh0t12 suggests using a derma pen for hair regrowth, as it helped them after using finasteride and minoxidil. Others discuss their experiences with various treatments, including derma rolling, oral and topical minoxidil, and finasteride, with mixed results.
A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.
The conversation discusses the fluctuation of testosterone levels in men under 40 and the difference between serum DHT and scalp DHT. It also mentions that DHT levels are higher on Dutasteride than on Finasteride, which is unusual.
The conversation is about someone taking dutasteride for hair loss since April 2023 but still experiencing shedding. They had blood tests for various levels and are seeking advice on their DHT levels and vitamin D.
Alfatradiol is discussed as a weak 5ARI and estrogen, not as effective as minoxidil, RU58841, or CB-03-01, but a safe alternative for those who can't use finasteride. Users express frustration over the lack of strong FDA-approved topical antiandrogens for hair loss.
Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.
Nearly 40% of adults with alopecia areata achieved at least 80% scalp hair coverage after 52 weeks of taking OLUMIANT® 4-mg. The conversation distinguishes this success from androgenetic alopecia, which is a different type of hair loss.
PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.